Advertisement

Newer Coronary Risk Factors

  • Peter W. F. Wilson
Chapter

Abstract

Although traditional coronary risk factors have included elevated blood pressure, cholesterol, and cigarette smoking, several other factors are now being considered. This chapter provides a sampling of some of these “newer” risk factors, particularly those that have a biologic basis. The major categories to be considered are hematologic, newer lipid particles and their metabolic considerations, vitamins and homocysteine, and aspects of glucose metabolism.

Keywords

Coronary Heart Disease Risk Homocysteine Level Carotid Stenosis Lipid Particle Heart Outcome Prevention Evaluation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Danesh J, Collins R, Appleby P, Peto R: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998, 279:1477–1482.CrossRefPubMedGoogle Scholar
  2. 2.
    Meade TW, Brozovic M, Chakrabarti RR, et al..: Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986, 2:533–537.CrossRefPubMedGoogle Scholar
  3. 3.
    Ridker PM, Vaughan DE, Stampfer MJ, et al..: Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993, 341:1165–1168.CrossRefPubMedGoogle Scholar
  4. 4.
    Thompson SG, Kienast J, Pyke SD, et al..: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995, 332:635–641.CrossRefPubMedGoogle Scholar
  5. 5.
    Gebara OCE, Mittleman MA, Sutherland P, et al..: Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995, 91:1952–1958.PubMedGoogle Scholar
  6. 6.
    Ballantyne CM, Hoogeveen RC, Bang H, et al..: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004, 109:837–842.CrossRefPubMedGoogle Scholar
  7. 7.
    Brennan ML, Penn MS, Van Lente F, et al..: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003, 349:1595–1604.CrossRefPubMedGoogle Scholar
  8. 8.
    Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836–843.CrossRefPubMedGoogle Scholar
  9. 9.
    Willich SN, Levy D, Rocco MB, et al.: Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol 1987, 60:801–806.CrossRefPubMedGoogle Scholar
  10. 10.
    Muller JE, Tofler GH, Stone PH: Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989, 79:733–743.PubMedGoogle Scholar
  11. 11.
    Schaefer EJ, Lamon-Fava S, Jenner JL, et al.: Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994, 271:999–1003.CrossRefPubMedGoogle Scholar
  12. 12.
    Ridker PM, Stampfer MJ, Hennekens CH: Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 1995, 273:1269–1273.CrossRefPubMedGoogle Scholar
  13. 13.
    Tsimikas S, Brilakis ES, Miller ER, et al.: Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005, 353:46–57.CrossRefPubMedGoogle Scholar
  14. 14.
    Danesh J, Wheeler JG, Hirschfield GM, et al.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387–1397.CrossRefPubMedGoogle Scholar
  15. 15.
    Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973–979.CrossRefPubMedGoogle Scholar
  16. 16.
    Ridker PM, Danielson E, Fonseca FA, et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359: 2195–2207.CrossRefPubMedGoogle Scholar
  17. 17.
    Collaboration AT: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71–86.CrossRefGoogle Scholar
  18. 18.
    CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329–1339.CrossRefGoogle Scholar
  19. 19.
    Yusuf S, Zhao F, Mehta SR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494–502.CrossRefPubMedGoogle Scholar
  20. 20.
    Austin MA, Breslow JL, Hennekens CH, et al.: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988, 260:1917–1921.CrossRefPubMedGoogle Scholar
  21. 21.
    Cromwell W, Otvos JD, Keyes MJ, et al.: LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—implications for LDL management. J Clin Lipidol 2007, 1:583–592.CrossRefPubMedGoogle Scholar
  22. 22.
    Liu J, Sempos C, Donahue RP, et al.: Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care 2005, 28:1916–1921.CrossRefPubMedGoogle Scholar
  23. 23.
    Wilson PW, Myers RH, Larson MG, et al.: Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 1994, 272:1666–1671.CrossRefPubMedGoogle Scholar
  24. 24.
    Wilson PWF, Schaefer EJ, Larson MG, Ordovas JM: Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arterioscler Thromb Vasc Biol 1996, 16:1250–1255.PubMedGoogle Scholar
  25. 25.
    Gofman JW, Young W, Tandy R: Ischemic heart disease, atherosclerosis, and longevity. Circulation 1966, 34:679–697.PubMedGoogle Scholar
  26. 26.
    Juhan-Vague I, Alessi MC: Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993, 70:138–143.PubMedGoogle Scholar
  27. 27.
    Buring JE, O’Connor GT, Goldhaber SZ, et al.: Decreased HDL2 and HDL3 Cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction. Circulation 1992, 85:22–29.PubMedGoogle Scholar
  28. 28.
    Stampfer MJ, Hennekens CH, Manson JE, et al.: Vitamin E consumption and risk of coronary heart disease in women. N Engl J Med 1993, 328:1444–1449.CrossRefPubMedGoogle Scholar
  29. 29.
    Steinberg D: A critical look at the evidence for the oxidation of LDL in atherogenesis. Atherosclerosis 1997, 131(Suppl):S5–S7.CrossRefPubMedGoogle Scholar
  30. 30.
    Alpha-tocopherol, Beta Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994, 330:1029–1035.CrossRefGoogle Scholar
  31. 31.
    Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.CrossRefPubMedGoogle Scholar
  32. 32.
    Yusuf S, Dagenais G, Pogue J, et al.: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:154–160.CrossRefPubMedGoogle Scholar
  33. 33.
    Christen WG, Ajani UA, Glynn RJ, Hennekens CH: Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med 2000, 160:422–434.CrossRefPubMedGoogle Scholar
  34. 34.
    Selhub J, Jacques PF, Bostom AG, et al.: Association between plasma homocysteine and extracranial carotid stenosis. N Engl J Med 1995, 332:286–291.CrossRefPubMedGoogle Scholar
  35. 35.
    Selhub J, Jacques PF, Wilson PWF, et al.: Vitamin status and intake as primary determinants of homocysteinemia in the elderly. JAMA 1993, 270:2693–2698.CrossRefPubMedGoogle Scholar
  36. 36.
    Sarnak MJ, Levey AS, Schoolwerth AC, et al.: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108:2154–2169.CrossRefPubMedGoogle Scholar
  37. 37.
    Jacques PF, Selhub J, Bostom AG, et al.: The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999, 340:1449–1454.CrossRefPubMedGoogle Scholar
  38. 38.
    Pyorala K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979, 2:131–141.CrossRefPubMedGoogle Scholar
  39. 39.
    Meigs JB, D’Agostino RB, Wilson PWF, et al.: Risk variable clustering in the insulin resistance syndrome. Diabetes 1997, 46:1594–1600.CrossRefPubMedGoogle Scholar
  40. 40.
    Kuusisto J, Mykkanen L, Pyorala K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994, 43:960–967.CrossRefPubMedGoogle Scholar
  41. 41.
    UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837–853.CrossRefGoogle Scholar
  42. 42.
    Wilson PW, Kauppila LI, O’Donnell CJ, et al.: Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 2001, 103:1529–1534.PubMedGoogle Scholar
  43. 43.
    Jarvisalo MJ, Jartti L, Nanto-Salonen K, et al.: Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children. Circulation 2001, 104:2943–2947.CrossRefPubMedGoogle Scholar
  44. 44.
    O’Leary DH, Polak JF, Kronmal RA, et al.: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999, 340:14–22.CrossRefPubMedGoogle Scholar
  45. 45.
    Newman AB, Naydeck BL, Sutton-Tyrrell K, et al.: Coronary artery calcification in older adults to age 99: prevalence and risk factors. Circulation 2001, 104:2679–2684.CrossRefPubMedGoogle Scholar
  46. 46.
    Zhao XQ, Yuan C, Hatsukami TS, et al.: Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 2001, 21:1623–1629.CrossRefPubMedGoogle Scholar
  47. 47.
    Nissen SE, Yock P: Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation 2001, 103:604–616.PubMedGoogle Scholar
  48. 48.
    Detrano R, Guerci AD, Carr JJ, et al.: Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008, 358:1336–1345.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Peter W. F. Wilson
    • 1
  1. 1.Cardiology Division, Atlanta Veterans Affairs Medical CenterRollins School of Public Health Emory UniversityAtlantaUSA

Personalised recommendations